Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
4
Neutral
3
Bullish
7
Bearish
35
Neutral
3
Bullish
8
Bearish
31
Neutral
0
Bullish
1
Discovery themes featuring this stock
Poly Medicure Limited is an India-headquartered medical devices manufacturer supplying infusion therapy, renal/dialysis, cardiology, orthopedics and other fluid-management products to over 125 countries, operating multiple manufacturing sites across India, China, Egypt and Italy and selling through a global distributor network and recently acquired European businesses.
Q3 FY26 consolidated revenue rose 16.4% YoY to Rs.493.7 crore with gross margin expansion (~300 bps YoY) but reported PAT compression due to one-off labour-code provisioning and acquisition-related expenses; consolidated operating EBITDA margin remains within the 25–27% guidance band at 24.2% for the quarter and 25.8% for 9M.
Strategic inorganic moves are material: Poly Medicure completed acquisitions of PendraCare and Citieffe in FY26, adding immediate revenue (~Rs.48–49 crore in Q3) and EU/FDA-approved products, while management is integrating operations and aiming to leverage India cost base to scale European technologies globally.
Innovation momentum is significant: 19 new products launched in 9M FY26, ~100 R&D staff across India, Italy and the Netherlands, 394 patents reported, and DCGI approvals for high-ASP cardiology devices (IVL and DEB) that are expected to lift ASPs and open new value pools.
Balance-sheet strength and capex plan: cash & equivalents ~Rs.840 crore at Dec 31, 2025 with Rs.234 crore capex in 9M FY26, land acquisition at YEIDA for a medical device park, and three planned plants coming online in 18–24 months to support growth and product upshift.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
13,667 Cr
Low Risk
42.4
38.6
2.1
4.4
2,318.35
1,184.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Poly Medicure Ltd (POLYMED) is currently trading at 1,359.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Poly Medicure Limited is an India-headquartered medical devices manufacturer supplying infusion therapy, renal/dialysis, cardiology, orthopedics and other fluid-management products to over 125 countries, operating multiple manufacturing sites across India, China, Egypt and Italy and selling through a global distributor network and recently acquired European businesses. Q3 FY26 consolidated revenue rose 16.4% YoY to Rs.493.7 crore with gross margin expansion (~300 bps YoY) but reported PAT compression due to one-off labour-code provisioning and acquisition-related expenses; consolidated operating EBITDA margin remains within the 25–27% guidance band at 24.2% for the quarter and 25.8% for 9M. Strategic inorganic moves are material: Poly Medicure completed acquisitions of PendraCare and Citieffe in FY26, adding immediate revenue (~Rs.48–49 crore in Q3) and EU/FDA-approved products, while management is integrating operations and aiming to leverage India cost base to scale European technologies globally. Innovation momentum is significant: 19 new products launched in 9M FY26, ~100 R&D staff across India, Italy and the Netherlands, 394 patents reported, and DCGI approvals for high-ASP cardiology devices (IVL and DEB) that are expected to lift ASPs and open new value pools. Balance-sheet strength and capex plan: cash & equivalents ~Rs.840 crore at Dec 31, 2025 with Rs.234 crore capex in 9M FY26, land acquisition at YEIDA for a medical device park, and three planned plants coming online in 18–24 months to support growth and product upshift.
Over the past 52 weeks, Poly Medicure Ltd has traded between a low of ₹1,184.00 and a high of ₹2,318.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Poly Medicure Ltd has a market capitalization of approximately 13,667.31. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Poly Medicure Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 42.43 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 13,667.31 Cr, Poly Medicure Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Poly Medicure Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Poly Medicure Ltd is 42.43. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations rose 21.25% YoY to ₹534.51 crore, while net profit fell 29.17% YoY to ₹65.04 crore. EBITDA was ₹112.1 crore with a 21% margin.
The company reported 12.3% growth in full-year FY26 consolidated revenue, with domestic business up 20% and international business up 9%.
Reports in the provided text put Q4 FY26 consolidated net profit at ₹65.04 crore (down 29.17% YoY) and ₹66.29 crore (down 27.81% YoY), depending on the source.
Capital Market data reported Q4 FY26 net profit at ₹66.29 crore, while a separate market report cited ₹65.04 crore for the same quarter.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1359.80 | 13,667 Cr | 42.43 | 4.40 | 0.26 | 10.37 | 12.71 | 8.18 | ||
37.86 | 2,494 Cr | 63.23 | 6.67 | 0.01 | 5.54 | 7.87 | 8.44 | ||
234.20 | 1,277 Cr | 44.06 | 5.25 | 0.00 | 13.74 | 14.03 | 8.99 | ||
207.10 | 1,109 Cr | 77.43 | 1.75 | 0.00 | 2.26 | 4.09 | 1.21 | ||
474.60 | 1,107 Cr | 24.55 | 2.56 | 0.00 | 21.29 | 14.24 | 0.00 | ||
492.85 | 877 Cr | 32.21 | 5.33 | 0.00 | 15.39 | 15.75 | 8.44 | ||
434.55 | 754 Cr | 73.60 | 4.33 | 0.00 | 5.88 | 7.65 | 5.02 | ||
| Median: 7 Co. | — | 434.55 | 1,109 Cr | 44.06 | 4.40 | 0.00 | 10.37 | 12.71 | 8.18 |
Earnings Transcript
Poly Medicure submitted the Q4/FY26 earnings call transcript: FY26 consolidated revenue INR 1,875 Cr (+12.3%), standalone INR 1,662 Cr (+4%), standalone EBITDA ~INR 446 Cr (~26.8% margin); Q4 standalone rev INR 443 Cr; discussed acquisitions (PendraCare, Citieffe, Medyneo), 35 new products, Brazil expansion and R&D/market integration plans.
Audited financial results
Poly Medicure published audited standalone & consolidated financial results for quarter and year ended Mar 31, 2026 (ad on May 26, 2026); consolidated revenue Rs 1,99,534.14 lacs and consolidated PAT Rs 32,072.99 lacs; unmodified audit opinion.
Audited financial results
Poly Medicure published audited standalone and consolidated results for Q4/FY2026: standalone revenue Rs 178,238.25 lacs and PAT Rs 33,598.49 lacs; consolidated revenue Rs 199,534.14 lacs and PAT Rs 32,072.99 lacs; auditors unmodified; exceptional labour-code impact Rs 680.40 lacs.
Audited Results & Dividend
Board approved audited standalone & consolidated results for Q4/FY26 with an unmodified opinion, recommended a dividend of Rs.3.50/share (70% of Rs.5) subject to shareholder approval, and re‑appointed PwC Services LLP and Oswal Sunil & Co. as internal auditors.
QIP Utilization Statement
Audit Committee reviewed utilization of QIP proceeds of ~Rs.99,999.98 lakh for the quarter ended Mar 31, 2026 and confirmed no deviation from stated objects; surplus Rs.34.39 lakh moved to GCP and balance transferred to monitoring account.
QIP Utilization
Poly Medicure's Audit Committee (25-May-2026) reviewed QIP proceeds of Rs.99,999.98 lakh (53,19,148 shares allotted at Rs.1,880) and reported no deviation in utilization; Rs.98,534.37 lakh remains in the monitoring account.
